Why Amgen Inc. (AMGN) is One of the Best Stem Cell Therapy Stocks to Buy

Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc. (NASDAQ:AMGN) with a Hold rating on April 21, setting a price target of $366. The firm told investors in a research note that the company has executed well on its key growth drivers, but this is reflected in the stock’s good performance since last October. It further stated that it believes Amgen Inc.’s (NASDAQ:AMGN) current valuation to be appropriate, adding that meaningful appreciation from here “could be more challenging” because of some loss of exclusivities and pricing pressure across several of its large mature products.

UBS Sees Continued Upside in Amgen (AMGN), Lifts Target to $400

For additional perspective, in its fiscal Q4 and full year 2025 results, Amgen Inc. (NASDAQ:AMGN) reported strong performance in the full year with double-digit growth in revenues and EPS. Total revenues for fiscal Q4 rose 9% to $9.9 billion compared to the prior year period, with product sales growing 7%, driven by 10% volume growth. Total revenues for the full year reached $36.8 billion, up 10% compared to the same quarter last year.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

While we acknowledge the risk and potential of AMZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.